Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Biosense Webster, a unit of Johnson & Johnson MedTech, will present findings from five studies on cardiac arrhythmia treatment at the 28th Annual International AF Symposium in Boston from February 2-4. Two late-breaking studies include the multicenter inspIRE study, analyzing a novel pulsed field ablation catheter, and the STELLAR study on a radiofrequency balloon catheter for pulmonary vein isolation. These studies emphasize the company’s commitment to innovation in electrophysiology. Attendees can engage with new technologies at exhibit booth #111, showcasing advanced catheter solutions.
Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on February 15 at 1:00 p.m. Eastern Time. The company will be represented by Biljana Naumovic, Worldwide Vice President, and Peter Lebowitz, Global Therapeutic Head for Oncology, in a virtual session. Investors can access the live audio webcast on the Johnson & Johnson website. A replay will be available approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Abiomed, Inc., with a transaction value of approximately $16.6 billion, or $380 per share in cash. The acquisition expands J&J's MedTech portfolio, particularly in the high-growth cardiovascular market, and is expected to be slightly dilutive to neutral to adjusted earnings per share in the first year. JJN anticipates this deal will enhance revenue growth in its MedTech segment and yield accretive effects starting in 2024. Abiomed’s stock ceased trading on NASDAQ following the merger on December 22, 2022.
Johnson & Johnson (NYSE: JNJ) has extended the expiration of its offer to acquire Abiomed, Inc. (NASDAQ: ABMD) for $380.00 per share, plus a potential $35.00 contingent value right. The new expiration date is set for December 21, 2022. As of December 13, 2022, about 19.3 million shares, or 42.75% of Abiomed's outstanding shares, have been tendered. The acquisition is conditional on the successful tendering of a majority of shares and receiving necessary regulatory approvals. Investors are encouraged to review related filings on the SEC's website for more details.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. (Eastern Time) on January 24 to discuss its fourth-quarter results. Key executives, including CEO Joaquin Duato and CFO Joseph J. Wolk, will lead the call. Interested parties can join via the company’s website or by phone. A replay will be available until February 7. The results are anticipated to provide insights into the company’s performance, which is crucial for stakeholders and market analysts.
Johnson & Johnson (NYSE: JNJ) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 9 at 12:45 p.m. ET in San Francisco, CA. CEO Joaquin Duato will represent the company during the session. The event will feature a live audio webcast accessible via the Johnson & Johnson investor website. An audio replay will be available approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) announced that CEO Joaquin Duato will take on the additional role of Chairman, effective January 2023, succeeding Alex Gorsky who steps down after 30 years. Duato, with over three decades at J&J, is recognized for his leadership and commitment to stakeholder value. The transition highlights the company's succession planning, with Duato poised to guide J&J through pivotal times. Both Gorsky's contributions and Duato's vision indicate a strategic focus on healthcare innovation and inclusivity.
ABIOMED, Inc. (NASDAQ: ABMD) reported financial results for the quarter ending September 30, 2022, with revenues reaching $266 million, marking an 11% increase in constant currency. This growth reflects the seventh consecutive quarter of double-digit constant currency growth. U.S. product revenue also increased by 10% to $208 million. However, procedural volumes were affected in July due to physician vacations and labor shortages, which improved by August and September. The company celebrated significant innovation milestones and FDA approvals.
Johnson & Johnson (NYSE: JNJ) has announced the acquisition of Abiomed (NASDAQ: ABMD) for $380.00 per share, valuing the deal at approximately $16.6 billion. The acquisition aims to enhance Johnson & Johnson’s MedTech segment, particularly in the cardiovascular space, addressing significant health needs related to heart failure. The acquisition is expected to be accretive to adjusted earnings starting in 2024. Abiomed's innovative technologies and strong growth potential will complement Johnson & Johnson's existing portfolio, facilitating market expansion in high-growth cardiovascular sectors.
Johnson & Johnson (NYSE: JNJ) reported Q3 2022 sales of $23.8 billion, a 1.9% increase from Q3 2021. Earnings per share (EPS) rose 22.6% to $1.68, while adjusted EPS decreased 1.9% to $2.55. Operational sales grew 8.1%, driven by strong performances in the pharmaceutical sector, particularly from drugs like DARZALEX and TREMFYA. The company is maintaining its full-year guidance for adjusted operational sales and EPS, despite adverse currency impacts. The quarter also saw significant regulatory approvals and a new $5 billion share repurchase program.